News of the WeekCancer Research

Why Some Leukemia Cells Resist STI-571

Science  22 Jun 2001:
Vol. 292, Issue 5525, pp. 2231-2233
DOI: 10.1126/science.292.5525.2231a

You are currently viewing the summary.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Summary

The antileukemia drug known as Gleevec or STI-571 has been heralded as the vanguard of a new generation of cancer chemotherapy agents, designed specifically to counteract the biochemical changes that make cells cancerous. Yet STI-571 shares an unfortunate characteristic with older, conventional drugs. Patients with advanced disease often relapse; their tumor cells become resistant and eventually grow out of control. Results published online by Science on 21 June (www.sciencexpress.org) now explain why this happens in STI-571, and perhaps point the way to improved therapies.

Related Content